Last reviewed · How we verify
Gut Microbial Transplantation
At a glance
| Generic name | Gut Microbial Transplantation |
|---|---|
| Also known as | GMT |
| Sponsor | Corewell Health West |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Neurocognitive Effects of FMT in MDD Patients With and Without IBS (PHASE2, PHASE3)
- Feasibility Study of MET-4: Evaluating Fecal Microbiome Effects in Immunotherapy Patients (PHASE2, PHASE3)
- Clostridioides Difficile: Understanding Responses and Treatment Effects
- Aging Resilience Through Microbiota Optimization and Regulation (PHASE1)
- Fecal Microbiota Transplantation for the Treatment of ICU Delirium (NA)
- Protective Effect of Probacine Against Negative Gut Metabolism and Organ Dysfunction After Cardiovascular Surgery (PANDA IV) (NA)
- Effect of Fecal Microbiota Transplantation (FMT) in Pediatric Functional Gastrointestinal Disorders (NA)
- Faecal Autologous Capsule Transplantation for Type 1 Diabetes Mellitus (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Gut Microbial Transplantation CI brief — competitive landscape report
- Gut Microbial Transplantation updates RSS · CI watch RSS
- Corewell Health West portfolio CI